NCT02480894View on ClinicalTrials.gov

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

PHASE1CompletedINTERVENTIONAL

Enrollment

112

Participants

Timeline

Start Date

July 7, 2015

Primary Completion Date

September 21, 2015

Study Completion Date

September 21, 2015

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

BMS-663068

BMS-663068

DRUG

Maraviroc

Maraviroc

Trial Locations (1)

78209

GSK Investigational Site, San Antonio

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY